Skip to main content
Top
Published in: Current Cardiology Reports 5/2015

Open Access 01-05-2015 | Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk

Authors: S. Wharton, K. J. Serodio

Published in: Current Cardiology Reports | Issue 5/2015

Login to get access

Abstract

Since the 1980s, the prevalence of obesity has almost doubled worldwide. Treatments for obesity include lifestyle modification, medications and surgery. Newer anti-obesity medications have been shown to be effective at inducing initial weight management in addition to successful long-term weight maintenance. Historically, weight management medications have been associated with public safety concerns that have resulted in the majority being withdrawn from the market or never receiving medicinal authorization. Recently, several countries have approved some newer generation weight management medications which may be beneficial to combat obesity. These medications have varying effects on cardiometabolic parameters, both positive and potentially negative. This review will outline the mechanisms of action of these medications and their implications for both diabetes and cardiovascular risks.
Literature
2.
go back to reference Herouvi D, Karanasios E, Karayianni C, et al. Cardiovascular disease in childhood: the role of obesity. Eur J Pediatr. 2013;172:721–32.CrossRefPubMed Herouvi D, Karanasios E, Karayianni C, et al. Cardiovascular disease in childhood: the role of obesity. Eur J Pediatr. 2013;172:721–32.CrossRefPubMed
3.
go back to reference Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol. 2013;9:467–78.CrossRefPubMed Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol. 2013;9:467–78.CrossRefPubMed
4.
go back to reference Carter R, Mouralidarane A, Ray S, et al. Recent advancements in drug treatment of obesity. Clin Med. 2012;12:456–60.CrossRefPubMed Carter R, Mouralidarane A, Ray S, et al. Recent advancements in drug treatment of obesity. Clin Med. 2012;12:456–60.CrossRefPubMed
7.
go back to reference Chan EW, He Y, Chui CSL, et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev. 2013;14:383–92.CrossRefPubMed Chan EW, He Y, Chui CSL, et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev. 2013;14:383–92.CrossRefPubMed
9.
go back to reference FDA. Contrave (naltrexone sr/bupropion SR combination): Advisory Committee Briefing Document. 2010;1–278. FDA. Contrave (naltrexone sr/bupropion SR combination): Advisory Committee Briefing Document. 2010;1–278.
10.
go back to reference Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav. 2010;97:63–83.CrossRefPubMed Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav. 2010;97:63–83.CrossRefPubMed
11.
go back to reference EMA. Guideline on clinical evaluation of medicinal products used in weight control. 2014;4:1–11. EMA. Guideline on clinical evaluation of medicinal products used in weight control. 2014;4:1–11.
13.
go back to reference Andraws R, Chawla P, Brown DL. Cardiovascular effects of ephedra alkaloids: a comprehensive review. Prog Cardiovasc Dis. 2005;47:217–25.CrossRefPubMed Andraws R, Chawla P, Brown DL. Cardiovascular effects of ephedra alkaloids: a comprehensive review. Prog Cardiovasc Dis. 2005;47:217–25.CrossRefPubMed
14.
go back to reference EMA. Press release: the European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. 2008;4–5. EMA. Press release: the European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. 2008;4–5.
15.
go back to reference Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71–7.CrossRefPubMed Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71–7.CrossRefPubMed
16.
go back to reference Connolly H, Crary J, McGoon M, et al. Vaulvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–8.CrossRefPubMed Connolly H, Crary J, McGoon M, et al. Vaulvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–8.CrossRefPubMed
17.
go back to reference Sweeting AN, Tabet E, Caterson ID, et al. Management of obesity and cardiometabolic risk—role of phentermine / extended release topiramate. Diabetes Metab Syndr Obes. 2014;12:35–44. Sweeting AN, Tabet E, Caterson ID, et al. Management of obesity and cardiometabolic risk—role of phentermine / extended release topiramate. Diabetes Metab Syndr Obes. 2014;12:35–44.
18.
go back to reference Hainer V, Hainerová IA. Do we need anti-obesity drugs? Diabetes Metab Res Rev. 2012;28 Suppl 2:8–20.CrossRefPubMed Hainer V, Hainerová IA. Do we need anti-obesity drugs? Diabetes Metab Res Rev. 2012;28 Suppl 2:8–20.CrossRefPubMed
19.
go back to reference EMA. European Medicines Agency recommends suspension of marketing authorisations for sibutramine. 2010;44:1–2. EMA. European Medicines Agency recommends suspension of marketing authorisations for sibutramine. 2010;44:1–2.
21.
go back to reference Sumithran P, Proietto J. Benefit-risk assessment of orlistat in the treatment of obesity. Drug Saf. 2014;37:597–608.CrossRefPubMed Sumithran P, Proietto J. Benefit-risk assessment of orlistat in the treatment of obesity. Drug Saf. 2014;37:597–608.CrossRefPubMed
22.
go back to reference Torgerson J, Hauptman J, Boldrin M, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.CrossRefPubMed Torgerson J, Hauptman J, Boldrin M, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.CrossRefPubMed
23.
go back to reference Erdmann J, Lippl F, Klose G, et al. Cholesterol lowering effect of dietary weight loss and orlistat treatment—efficacy and limitations. Aliment Pharmacol Ther. 2004;19:1173–9.CrossRefPubMed Erdmann J, Lippl F, Klose G, et al. Cholesterol lowering effect of dietary weight loss and orlistat treatment—efficacy and limitations. Aliment Pharmacol Ther. 2004;19:1173–9.CrossRefPubMed
24.
go back to reference Ransom T, Goldenberg R, Mikalachki A, et al. Reducing the risk of developing diabetes. Can J diabetes. 2013;37 Suppl 1:S16–9.CrossRefPubMed Ransom T, Goldenberg R, Mikalachki A, et al. Reducing the risk of developing diabetes. Can J diabetes. 2013;37 Suppl 1:S16–9.CrossRefPubMed
25.
go back to reference Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102–38.CrossRefPubMed Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102–38.CrossRefPubMed
26.
go back to reference Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015.
27.
go back to reference Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–42.CrossRef Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–42.CrossRef
28.•
go back to reference FDA. New Drug Application 22580- VI-0521 QNEXA (phentermine/topiramate). 2012;1–200. This report summarized MACE data and it was determined that there was no significant difference in the risk of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke between phentermine-topiramate and placebo. FDA. New Drug Application 22580- VI-0521 QNEXA (phentermine/topiramate). 2012;1–200. This report summarized MACE data and it was determined that there was no significant difference in the risk of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke between phentermine-topiramate and placebo.
29.
go back to reference Woloshin S, Schwartz L. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? JAMA Intern Med. 2014;174:615–9.CrossRefPubMed Woloshin S, Schwartz L. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? JAMA Intern Med. 2014;174:615–9.CrossRefPubMed
30.
go back to reference Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.CrossRefPubMed Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.CrossRefPubMed
31.
go back to reference Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine / topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study 1–3. 2012;297–308. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine / topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study 1–3. 2012;297–308.
33.
go back to reference O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–36.CrossRefPubMed O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–36.CrossRefPubMed
34.
go back to reference Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.CrossRefPubMed Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.CrossRefPubMed
35.
go back to reference EMA. Assessment report-Belviq. 2013;44:1–43. EMA. Assessment report-Belviq. 2013;44:1–43.
36.
go back to reference Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77.CrossRefPubMed Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77.CrossRefPubMed
39.
go back to reference Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21:935–43.CrossRefPubMedCentralPubMed Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21:935–43.CrossRefPubMedCentralPubMed
40.
go back to reference Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.CrossRefPubMed Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.CrossRefPubMed
41.
go back to reference Hollander P, Gupta A, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.CrossRefPubMedCentralPubMed Hollander P, Gupta A, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.CrossRefPubMedCentralPubMed
42.
go back to reference Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110–20.CrossRefPubMed Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110–20.CrossRefPubMed
43.
go back to reference Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.CrossRefPubMedCentralPubMed Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.CrossRefPubMedCentralPubMed
44.
go back to reference Novo Nordisk. Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo. 2014;1–4. Novo Nordisk. Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo. 2014;1–4.
45.
go back to reference FDA. Highlight of prescribing information Victoza. 2010;1–23. FDA. Highlight of prescribing information Victoza. 2010;1–23.
48.
go back to reference Novo Nordisk. Novo Nordisk receives Health Canada approval for Saxenda® (liraglutide) for the treatment of chronic weight management. Available at: http://www.newswire.ca/en/story/1494067/novo-nordisk-receives-health-canada-approval-for-saxenda-liraglutide-for-the-treatment-of-chronic-weight-management#. Accessed 13 Mar 2015. Novo Nordisk. Novo Nordisk receives Health Canada approval for Saxenda® (liraglutide) for the treatment of chronic weight management. Available at: http://​www.​newswire.​ca/​en/​story/​1494067/​novo-nordisk-receives-health-canada-approval-for-saxenda-liraglutide-for-the-treatment-of-chronic-weight-management#. Accessed 13 Mar 2015.
49.
go back to reference Novo Nordisk. Novo Nordisk reports 8 % weight loss in phase 3a obesity trial with liraglutide 3 mg. 2013;24–26. Novo Nordisk. Novo Nordisk reports 8 % weight loss in phase 3a obesity trial with liraglutide 3 mg. 2013;24–26.
50.
go back to reference Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–16.CrossRefPubMed Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–16.CrossRefPubMed
51.••
go back to reference Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443–51. This SCALE trial found numerous positive cardiometabolic effects of liraglutide 3.0 mg and is one of the defining studies used to assess the safety of liraglutide for weight management.CrossRef Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443–51. This SCALE trial found numerous positive cardiometabolic effects of liraglutide 3.0 mg and is one of the defining studies used to assess the safety of liraglutide for weight management.CrossRef
52.
go back to reference Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.CrossRefPubMedCentralPubMed Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.CrossRefPubMedCentralPubMed
53.
go back to reference Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–81.CrossRefPubMed Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–81.CrossRefPubMed
54.
go back to reference Zinman B, Gerich J, Buse J, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224–30.CrossRefPubMedCentralPubMed Zinman B, Gerich J, Buse J, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224–30.CrossRefPubMedCentralPubMed
55.
go back to reference Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55.CrossRefPubMedCentralPubMed Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55.CrossRefPubMedCentralPubMed
56.
go back to reference Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8:237–40.CrossRefPubMed Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8:237–40.CrossRefPubMed
57.
go back to reference George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014;19:65–76.CrossRefPubMed George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014;19:65–76.CrossRefPubMed
58.
go back to reference Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1906–13.CrossRefPubMed Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1906–13.CrossRefPubMed
60.
go back to reference Jackson VM, Price DA, Carpino PA. Investigational drugs in phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Expert Opin Investig Drugs. 2014;23:1055–66.CrossRefPubMed Jackson VM, Price DA, Carpino PA. Investigational drugs in phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Expert Opin Investig Drugs. 2014;23:1055–66.CrossRefPubMed
61.
go back to reference Gadde KM, Yonish GM, Foust MS, et al. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. 2007;1227–30. Gadde KM, Yonish GM, Foust MS, et al. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. 2007;1227–30.
62.••
go back to reference Orexigen Therapeutics Inc. Emaptic. 2014. Available at: http://www.orexigen.com/programs/empatic.html. Accessed 26 Nov 2014. This web page outlined some of the only available data on the effectiveness of Empatic (bupropion-zonisamide slow-release compound) a promising weight management medication undergoing phase III clinical testing. Orexigen Therapeutics Inc. Emaptic. 2014. Available at: http://​www.​orexigen.​com/​programs/​empatic.​html. Accessed 26 Nov 2014. This web page outlined some of the only available data on the effectiveness of Empatic (bupropion-zonisamide slow-release compound) a promising weight management medication undergoing phase III clinical testing.
63.
go back to reference Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. 2009;17:1736–43. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. 2009;17:1736–43.
Metadata
Title
Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk
Authors
S. Wharton
K. J. Serodio
Publication date
01-05-2015
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 5/2015
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-015-0590-z

Other articles of this Issue 5/2015

Current Cardiology Reports 5/2015 Go to the issue

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Statin Intolerance: Diagnosis and Remedies

Interventional Cardiology (S Rao, Section Editor)

Transradial Intervention in ST Elevation Myocardial Infarction

Cardiac PET, CT, and MRI (SE Petersen, Section Editor)

Interventional CMR: Clinical Applications and Future Directions

Ischemic Heart Disease (D Mukherjee, Section Editor)

Cardiovascular, Renal and Overall Health Outcomes After Bariatric Surgery